Evaluating the Safety and Efficacy of the Maurora® DES in ICAS

Inclusion Criteria:

1. Age from 18 to 80 years;

2. Symptomatic intracranial atherosclerosis (Definition: Stroke or transient ischemicattack [TIA] associated with intracranial atherosclerosis within 90 days ofenrollment);

3. A major intracranial artery (carotid artery, MCA stem [M1], vertebral artery, orbasilar artery) with 70% to 99% stenosis on the angiography (According to WASIDmethod);

4. The target lesion length ≤15 mm and the vessel diameter between 2.5mm and 5.0mm,distal vessel diameter >1.5mm;

5. Only one stent planned for the target lesion;

6. A Modified Rankin Score of ≤ 3;

7. Patients understand the purpose and requirements of the study, and can makehim/herself understood, and has provided informed consent.

Exclusion Criteria:

1. Ischemic stroke within 2 weeks before the procedure;

2. Tandem extracranial or intracranial stenosis (70%-99%) of the target lesion;

3. Patients with stroke caused by perforating artery occlusion;

4. Severe calcification at target lesion;

5. Any history of brain parenchymal or other intracranial subarachnoid, subdural orextradural hemorrhage in the past 6 weeks;

6. History of stenting or angioplasty of an intracranial artery;

7. Intracranial tumor, aneurysm or intracranial arteriovenous malformation;

8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including:moya-moya disease, vasculitis disease, herpes zoster, varicella-zoster or otherviral vascular diseases, neurosyphilis, any other intracranial infections,radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease,neurofibromatosis, central nervous system benign vascular disease, post-partumvascular disease, suspected vasospasm, suspicious embolism recanalization;

9. Presence of any unequivocal cardiac source of embolism (e.g. atrial fibrillation);

10. Those who cannot tolerate general anesthesia due to insufficiency of cardiac orpulmonary function, not suitable for procedure;

11. Known allergy or contraindication to heparin, aspirin, ticlopidine, ticagrelor,sirolimus, anaesthetics and contrast agents;

12. Severe renal and hepatic insufficiency (ALTor AST > 3x upper limit, creatinine > 1.5x upper limit);

13. Major surgery within the past 30 days or planned within 90 days, or requiringsimultaneous intervention to renal artery, iliac artery, and coronary artery;

14. Life expectancy <12 months;

15. Pregnant or lactating women, or planning for pregnancy;

16. Participated in another investigational device or drug study within 30 days;

17. According to the judgement of the investigator, other situations that are notsuitable for enrollment.